“Who invented the VLP cervical cancer vaccines?”. Journal of the National Cancer Institute98 (7): 433. (April 2006). doi:10.1093/jnci/djj144. PMID16595773.
Haupt, Richard M.; Sings, Heather L. (2011). “The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil”. Journal of Adolescent Health49 (5): 467-475. doi:10.1016/j.jadohealth.2011.07.003. PMID22018560.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009). “Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis”. Int. J. Cancer124 (7): 1626-1636. doi:10.1002/ijc.24116. PMID19115209.
Martínez-Lavín, Manuel; Amezcua-Guerra, Luis (2017). “Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series”. Clinical Rheumatology36 (10): 2169–2178. doi:10.1007/s10067-017-3768-5. PMID28730271.
Zuckerman, J. N. (2006). “Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines”. Journal of Medical Virology78 (2): 169-177. doi:10.1002/jmv.20524. PMID16372285.
“Who invented the VLP cervical cancer vaccines?”. Journal of the National Cancer Institute98 (7): 433. (April 2006). doi:10.1093/jnci/djj144. PMID16595773.
Haupt, Richard M.; Sings, Heather L. (2011). “The Efficacy and Safety of the Quadrivalent Human Papillomavirus 6/11/16/18 Vaccine Gardasil”. Journal of Adolescent Health49 (5): 467-475. doi:10.1016/j.jadohealth.2011.07.003. PMID22018560.
Tay, S. K. (2012). "Cervical cancer in the human papillomavirus vaccination era". Current Opinion in Obstetrics and Gynecology 24 (1): 3-7. PMID22123221.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (2009). “Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis”. Int. J. Cancer124 (7): 1626-1636. doi:10.1002/ijc.24116. PMID19115209.
Martínez-Lavín, Manuel; Amezcua-Guerra, Luis (2017). “Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series”. Clinical Rheumatology36 (10): 2169–2178. doi:10.1007/s10067-017-3768-5. PMID28730271.
Zuckerman, J. N. (2006). “Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines”. Journal of Medical Virology78 (2): 169-177. doi:10.1002/jmv.20524. PMID16372285.
アメリカ合衆国特許第 7,476,389号, titled "Papilloma Virus Vaccines", was granted to co-inventors イアン・フレイザー（英語版） and 周建 (Zhou posthumously) on 13 January 2009. Its U.S. application was filed on 19 January 1994, but claimed priority under a 20 July 1992, PTC filing to the date of an initial [AU] Australian patent application filed on 19 July 1991.
"GACVS found no evidence to suggest a causal link with the HPV vaccine" : Global Advisory Committee on Vaccine Safety (12 March 2014). Statement on the continued safety of HPV vaccination(pdf) (Report). 2018年3月10日閲覧。
"GACVS found no evidence to suggest a causal link with the HPV vaccine" : Global Advisory Committee on Vaccine Safety (12 March 2014). Statement on the continued safety of HPV vaccination(pdf) (Report). 2018年3月10日閲覧。
アメリカ合衆国特許第 7,476,389号, titled "Papilloma Virus Vaccines", was granted to co-inventors イアン・フレイザー（英語版） and 周建 (Zhou posthumously) on 13 January 2009. Its U.S. application was filed on 19 January 1994, but claimed priority under a 20 July 1992, PTC filing to the date of an initial [AU] Australian patent application filed on 19 July 1991.
